Similarly, in the ovarian cancer, L1CAM tends to be expressed at the advancing edge of the tumor and in all examined patients its expression correlates with high-grade histopathology (G3), advanced FIGO stage, risk of incomplete debulking at primary surgery, lymph node involvement as well as overall and disease-free survival [10, 23, 44]. Here, L1CAM is linked to neoplasm.